How is Selinexor currently being studied in myeloma?
Selinexor is being evaluated in several clinical trials in relapsed and/or refractory myeloma, including:
- In combination with dexamethasone in a Phase 2b study (STORM) in patients whose myeloma is refractory to Velcade® (bortezomib, Takeda Oncology), Revlimid® (lenalidomide, Celgene), Kyprolis® (carfilzomib, Onyx Therapeutics), and Pomalyst® (pomalidomide, Celgene)
- In combination with the backbone treatments Pomalyst-dex, Velcade-dex or Revlimid-dex in a Phase 1b/2 study (STOMP)
- In combination with Doxil® (doxorubicin HCl liposome injection, Janssen) in a Phase1/2 study
- In combination with Kyprolis and dexamethasone in a Phase 1 study